Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Lung03: T-DXd and Immunotherapy With/Without Chemotherapy in First-line HER2-overexpressing NSCLC
NCT04686305Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 19
01
Overview
Phase 1, randomised, open-label trial of trastuzumab deruxtecan in non-small cell lung cancer (NSCLC) (10 arms), sponsored by AstraZeneca. Primary endpoint: Frequency of Adverse Events and Serious Adverse Events at 20 months. Started Mar 2021; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04686305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04686305.